Defining the future
Life Sciences in Greater Manchester
Where breakthrough science moves faster – from discovery to real-world impact
Greater Manchester is one of the UK’s leading life sciences regions, combining world-class clinical research, real-world data excellence and a uniquely connected health and innovation system. With consistent growth above the UK average for more than a decade, the region has quickly become one of the UK’s fastest-growing life sciences and health economies, and a place where innovation doesn’t stall between lab, clinic and market.
This is a city of firsts. From Rutherford splitting the atom, to the world’s first IVF baby, pioneering hip replacements, bionic eye implants and most recently the world’s first human procedure using a graphene-based brain-computer interface, Greater Manchester has repeatedly reshaped global healthcare.
Today, that legacy is powering the next generation of precision medicine, diagnostics, digital health and advanced therapies.
Why Greater Manchester?
Life sciences companies invest in Greater Manchester because it offers scale, speed and certainty, from early-stage R&D to clinical validation and commercial deployment.
Key advantages include:
- A secure, intelligent health data environment and shared care record for 2.8 million people
- One of the UK’s largest and most diverse populations, offering a truly global clinical trial pool
- Some of the UK’s leading research and teaching hospitals, including Europe’s largest oncology centre
- Five world-class universities driving research, collaboration and recruitment
- A unique square-mile life sciences campus in the city centre
- A fast-track adoption pathway via Health Innovation Manchester
- A wide selection of lab space, offices and specialist facilities for businesses of all sizes
- Excellent road, rail and air connectivity, including a global international airport
A connected system built for real-world impact
Greater Manchester’s life sciences strength lies in its joined-up approach. The region operates as a single, collaborative ecosystem, aligning the NHS, universities, local government and industry to accelerate innovation and adoption.
This integrated system enables companies to test, model, validate and deploy innovations faster than in fragmented markets. It also underpins the region’s leadership in real-world evidence, clinical trials and data-driven healthcare, with some of the UK’s highest trial delivery rates and start-up times 50% faster than the national average.
What People Say About Us
“At Seda, we deeply value the support provided by Invest Manchester in helping us establish and grow within Greater Manchester’s thriving bio ecosystem. Their guidance has been valuable in connecting us to a network of world-class talent, innovation, and opportunity.”
SEDA
Strength across life sciences specialisms
Clinical trials and real-world evidence
Greater Manchester is a major UK hub for real-world evidence and clinical trials, supported by a secure data environment and an integrated care record spanning primary, secondary and social care.
- Over 80% delivery rates across trials
- One of the fastest regions in the UK to initiate studies
- Leading performance through the NIHR Research Delivery Network
- Strong capability in decentralised, digital and electronic trials
Organisations such as NorthWest EHealth provide FDA-approved systems for fully electronic RCTs, reinforcing the region’s reputation for safe, scalable and validated research delivery.
Oncology and advanced therapies
Greater Manchester sits at the forefront of global cancer research and treatment. The Christie NHS Foundation Trust is Europe’s largest single-site cancer hospital, treating more than 60,000 patients annually and housing pioneering capabilities including proton beam therapy and MRI-guided radiotherapy. Together with the Manchester Cancer Research Centre, Cancer Research UK and the University of Manchester, the region delivers world-leading translational research in oncology.
Greater Manchester was among the first NHS regions to deliver CAR-T cell therapy, transforming treatment for leukaemia and lymphoma. This leadership now extends into genomics, proteomics and biomarker discovery, positioning the region as a prime location for advanced therapies and precision oncology businesses.
Precision medicine and genomics
The region hosts one of the NHS’s seven Genomic Laboratory Hubs, based at Manchester University NHS Foundation Trust, alongside the nationally recognised Manchester Centre for Genomic Medicine.
Together with institutions such as the Stoller Biomarker Discovery Centre and the NIHR Manchester Biomedical Research Centre, Greater Manchester offers an unrivalled network supporting personalised diagnostics, targeted therapies and molecular profiling – from discovery through to clinical adoption.
Diagnostics
Manchester has been named an “exemplar site” by the UK Government for the development and deployment of new diagnostics.
During the COVID-19 pandemic, local companies including QIAGEN, Novacyt and APIS Assay Technologies played a critical role in diagnostics development and outbreak response. Today, facilities such as the Manchester Molecular Pathology Innovation Centre support the translation of research into validated clinical tests, creating a de-risked route to market for diagnostics innovators.
Digital health and in silico medicine
Greater Manchester offers one of the UK’s most advanced environments for digital health and in silico medicine, combining AI, data science, cyber security and NHS integration.
The University of Manchester hosts the UK’s first In Silico Regulatory Science and Innovation Centre of Excellence (UK CEiRSI) which is pioneering the use of digital modelling, simulation and AI to support virtual trials and safer, faster product approval.
With strengths across bioinformatics, predictive modelling, AR/VR and health analytics, the region enables companies to explore new frontiers in treatment development, disease prevention and connected care.
Healthy ageing
As the UK’s first WHO-recognised age-friendly city region, Greater Manchester is a European leader in healthy ageing innovation. The region’s four-star reference site status reflects its work across community health, medical science and assistive technologies – supporting businesses developing solutions for ageing populations worldwide.
A connected system built for real-world impact
Greater Manchester’s life sciences strength lies in its joined-up approach. The region operates as a single, collaborative ecosystem, aligning the NHS, universities, local government and industry to accelerate innovation and adoption.
This integrated system enables companies to test, model, validate and deploy innovations faster than in fragmented markets. It also underpins the region’s leadership in real-world evidence, clinical trials and data-driven healthcare, with some of the UK’s highest trial delivery rates and start-up times 50% faster than the national average.
Support from day one
Invest Manchester provides free, confidential and tailored support to life sciences businesses looking to locate, grow or scale in Greater Manchester – from property and talent to partnerships, funding and introductions across the ecosystem.
Whether you’re developing diagnostics, advancing therapies, scaling digital health platforms or validating real-world evidence, Greater Manchester offers the environment, expertise and momentum to move faster, and go further.
Andrea Winders
Head of Sector, Life Sciences
- An expert with vast experience within the Life Science sector, infrastructure and smart cities
- Works closely with international partners, businesses and governments to attract and retain growing life science organisa